Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics advancing lead candidate targeting prostate cancer towards FDA submission
09:21am, Monday, 13'th Jan 2025
Candel Therapeutics Inc (NASDAQ:CADL) has provided a corporate update, highlighting anticipated milestones for this year building upon significant achievements in 2024. Updated overall survival dat
Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025
08:00am, Monday, 13'th Jan 2025
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic
Best-Performing Stocks Of 2024
11:46pm, Thursday, 02'nd Jan 2025
Best-Performing Stocks Of 2024
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases
02:41pm, Monday, 23'rd Dec 2024
In the New Year, many small-cap biotech companies will be advancing promising clinical trials with innovative therapies aimed at addressing significant unmet medical needs. Key trials include those fo
Candel Therapeutics rides high on promising Phase 3 data, funding boost
03:16pm, Thursday, 19'th Dec 2024
Candel Therapeutics Inc (NASDAQ:CADL) shares skyrocketed by nearly 43% on Thursday following a string of positive news surrounding the company's cancer drug pipeline. Last week the Needham, Massachuse
Candel Therapeutics raises $92M in public offering following prostate cancer trial success
04:26pm, Monday, 16'th Dec 2024
Candel Therapeutics Inc (NASDAQ:CADL) announced on Monday the completion of a public offering that raised approximately $92 million in gross proceeds. The offering included 12 million shares of common
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immuno
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
08:53am, Friday, 13'th Dec 2024
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Friday.
Candel Therapeutics unveils $80M public offering
08:48am, Friday, 13'th Dec 2024
Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants. The offering includes approximately 10 million shares of c
Candel Therapeutics Announces Pricing of Public Offering
11:00pm, Thursday, 12'th Dec 2024
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immuno
Candel Therapeutics Announces $80 Million Proposed Public Offering
04:51pm, Thursday, 12'th Dec 2024
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immuno
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal
11:36am, Thursday, 12'th Dec 2024
Candel stock rallies 68% on meeting the primary goal in a phase III study of CAN-2409 combo therapy compared to SOC radiation therapy for prostate cancer.
Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight
12:19pm, Wednesday, 11'th Dec 2024
Candel's phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Financially, CADL holds $16.6 million in c
Biotech Stock Hits 3-Year Highs on Trial Results
10:55am, Wednesday, 11'th Dec 2024
Candel Therapeutics Inc (NASDAQ:CADL) is soaring today, up 164% at $12.17 at last glance and earlier hitting a three-year high of $14.60, after the biotech company's prostate cancer immunotherapy tre
Candel Therapeutics Stock Surges Over 100% - Here's Why
09:19am, Wednesday, 11'th Dec 2024
On Wednesday, Candel Therapeutics, Inc. CADL announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients.
